ClinicalTrials.gg
CompletedNCT03872453Updated Sep 25, 2023Results posted

Acute Treatment Trial in Adult Subjects With Migraines

A Phase 2/3 interventional study of Zavegepant and Zavegepant matching placebo in Migraine, sponsored by Pfizer. Completed at 82 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-25.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
2,154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing zavegepant in Migraine Disorders — 4 open to participants now, 4 under way, none of them phase 3. zavegepant · Migraine Disorders.

Enrollment
Largest of 12
2,154 · median 225
Started
2019
the only one that year
Phase 2/3
3 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
8 of 12
Pfizer

Among the 12 studies testing zavegepant in Migraine Disorders, this one has the largest enrollment, is the only one that started in 2019, is one of 3 in phase 2/3, and was the 1st registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

4 of the 12 studies testing zavegepant in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About zavegepant

zavegepant: first FDA approval 2023 (ZAVZPRET). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing zavegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.

03

Conditions studied

  • Migraine

Keywords

  • Acute Migraine
  • phonophobia
  • photophobia
  • nausea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Key Inclusion Criteria:

  1. Participants have at least 1-year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition, including the following:
  1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
  2. Migraine attacks, on average, lasting about 4-72 hours if untreated.
  3. Not more than 8 attacks of moderate to severe intensity per month within the last 3 months.
  4. At least 2 consistent migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit and throughout the Screening Period.
  5. Less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and throughout the Screening Period.
  6. Participants on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to Screening Visit and the dose is not expected to change during the course of the study.
  7. Participants with for use of triptans may be included provided they meet all other study entry criteria.

Exclusion criteria

Exclusion Criteria:

Key Exclusion Criteria:

  1. Participant with a history of basilar migraine or hemiplegic migraine.
  2. Participant with a history of (HIV) disease.
  3. Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke or during the 6 months prior to screening.
  4. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however subjects can be included who have stable hypertension and/or diabetes for at least 3 months prior to being enrolled).
  5. Participant has a current diagnosis of major depression, other pain syndromes, psychiatric conditions (for example, schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion might interfere with study assessments.
  6. Participant has a history of gastric, or small intestinal surgery (including gastric bypass, gastric banding, gastric sleeve, gastric balloon, etc.), or has disease that causes malabsorption.
  7. The participant has a history of current or evidence of any significant and/ or unstable medical conditions (for example, history of congenital heart disease or arrhythmia, known suspected infection, or C, or cancer) that, in the Investigator's opinion, would expose them to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial.
  8. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or subjects who have met Fifth edition (DSM-V) criteria for any significant substance use disorder within the past 12 months from the date of the Screening Visit.
  9. History of nasal surgery in the 6 months preceding the Screening Visit.
  10. Participation in any other clinical trial while participating in this clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,154 participants (actual)

Study arms

  • Experimental
    Zavegepant 5 mg

    Participants administered a single intranasal dose of zavegepant 5 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar Unidose System (UDS) liquid spray device.

    Drug: Zavegepant · Device: Intranasal Aptar Pharma Unit Dose System

  • Experimental
    Zavegepant 10 mg

    Participants administered a single intranasal dose of zavegepant 10 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.

    Drug: Zavegepant · Device: Intranasal Aptar Pharma Unit Dose System

  • Experimental
    Zavegepant 20 mg

    Participants administered a single intranasal dose of zavegepant 20 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.

    Drug: Zavegepant · Device: Intranasal Aptar Pharma Unit Dose System

  • Placebo comparator
    Placebo

    Participants administered a single intranasal dose of zavegepant-matching placebo on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.

    Drug: Zavegepant matching placebo · Device: Intranasal Aptar Pharma Unit Dose System

Interventions

  • A single dose of zavegepant

    Also known as: BHV3500

  • DrugZavegepant matching placebo

    A single dose of placebo matched to zavegepant

  • DeviceIntranasal Aptar Pharma Unit Dose System

    A single-dose intranasal device

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Freedom From Pain at 2 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic clinical outcome assessment (eCOA) handheld device. Pain freedom was defined as pain level of none post-dose.

    Time frame: 2 hours post-dose

  2. Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose

    MBS was reported as nausea, photophobia, or phonophobia at migraine onset using the eCOA handheld device. Symptom status (absent, present) was assessed post-dose using the eCOA handheld device separately for nausea, photophobia, and phonophobia. Freedom from MBS was defined as MBS reported at on-study migraine attack onset that was absent post-dose.

    Time frame: 2 hours post-dose

Secondary outcomes

  1. Percentage of Participants With Pain Relief at 2 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

    Time frame: 2 hours post-dose

  2. Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose

    Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

    Time frame: 2 hours post-dose

  3. Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose

    Participants who did not experience relief of their migraine headache at the end of 2 hours after dosing with study medication (and after the 2-hour assessments had been completed on the eCOA handheld device) were permitted to use the following rescue medications: aspirin, ibuprofen, acetaminophen up to 1000 mg/day (this includes Excedrin® Migraine), naproxen (or any other type of nonsteroidal anti-inflammatory drug), antiemetics (for example, metoclopramide or promethazine), or baclofen. The participant's use of rescue medication was recorded by the site on a case report form.

    Time frame: Through 24 hours post-dose

  4. Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose

    Photophobia (sensitivity to light) status was measured as absent or present in the eCOA handheld device. Freedom from photophobia was defined as photophobia absent post-dose in the subset of participants with photophobia present at on-study migraine attack onset.

    Time frame: 2 hours post-dose

  5. Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose

    Phonophobia (sensitivity to sound) status was measured as absent or present in the eCOA handheld device. Freedom from phonophobia was defined as phonophobia absent post-dose in the subset of participants with phonophobia present at on-study migraine attack onset.

    Time frame: 2 hours post-dose

  6. Percentage of Participants With Pain Relief at 60 Minutes Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

    Time frame: 60 minutes post-dose

  7. Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose

    Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

    Time frame: 60 minutes post-dose

  8. Percentage of Participants With Pain Relief at 30 Minutes Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

    Time frame: 30 minutes post-dose

  9. Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose

    Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

    Time frame: 30 minutes post-dose

  10. Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 24 hours post-dose.

    Time frame: From 2 hours up to 24 hours post-dose

  11. Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 24 hours post-dose.

    Time frame: From 2 hours up to 24 hours post-dose

  12. Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 48 hours post-dose.

    Time frame: From 2 hours up to 48 hours post-dose

  13. Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 48 hours post-dose.

    Time frame: From 2 hours up to 48 hours post-dose

  14. Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose

    Nausea status was measured as absent or present in the eCOA handheld device. Freedom from nausea was defined as nausea absent post-odse in the subset of participants with nausea present at on-study migraine attack onset.

    Time frame: 2 hours post-dose

  15. Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relapse was defined as pain level of mild, moderate, or severe after 2 hours up to 48 hours post-dose in the subset of participants with pain level of none at 2 hours post-dose.

    Time frame: From 2 hours up to 48 hours post-dose

07

Results

Posted Oct 13, 2022

Participant flow

The study was conducted at 82 sites in the United States.

Participant flow — Overall Study
MilestoneZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Started418417418420
Treated388394403403
Modified intent-to-treat (mitt) participants387391402401
Completed386391399402
Not completed32261918
Withdrew: Adverse event1100
Withdrew: Lost to follow-up8744
Withdrew: Never treated migraine19171312
Withdrew: Pregnancy1000
Withdrew: Protocol deviation2002
Withdrew: Withdrawal by subject0120
Withdrew: Other than specified1000

Outcome measures

PrimaryPercentage of Participants With Freedom From Pain at 2 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic clinical outcome assessment (eCOA) handheld device. Pain freedom was defined as pain level of none post-dose.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Freedom From Pain at 2 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Freedom From Pain at 2 Hours Post-dose19.6 (14.8 to 24.5)22.5 (17.5 to 27.6)23.1 (18.1 to 28.2)15.5 (11.1 to 19.8)
Statistical analysis
  • Zavegepant 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1214 (Threshold for significance at 0.0167 level.) · Stratified percentage difference: 4.2 · 98.3% CI -2.3 to 10.7
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0113 (Threshold for significance at 0.0167 level.) · Stratified percentage difference: 7.0 · 98.3% CI 0.4 to 13.7
  • Zavegepant 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0055 (Threshold for significance at 0.0167 level.) · Stratified percentage difference: 7.7 · 98.3% CI 1.1 to 14.3
PrimaryPercentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose

MBS was reported as nausea, photophobia, or phonophobia at migraine onset using the eCOA handheld device. Symptom status (absent, present) was assessed post-dose using the eCOA handheld device separately for nausea, photophobia, and phonophobia. Freedom from MBS was defined as MBS reported at on-study migraine attack onset that was absent post-dose.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose39.0 (33.1 to 45.0)41.9 (36.0 to 47.9)42.5 (36.6 to 48.4)33.7 (28.0 to 39.3)
Statistical analysis
  • Zavegepant 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1162 (Threshold for significance at 0.0167 level.) · Stratified percentage difference: 5.4 · 98.3% CI -2.8 to 13.6
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0155 (Threshold for significance at 0.0167 level.) · Stratified percentage difference: 8.3 · 98.3% CI 0.1 to 16.5
  • Zavegepant 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0094 (Threshold for significance at 0.0167 level.) · Stratified percentage difference: 8.9 · 98.3% CI 0.7 to 17.0
SecondaryPercentage of Participants With Pain Relief at 2 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Pain Relief at 2 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Pain Relief at 2 Hours Post-dose57.9 (51.9 to 63.9)60.6 (54.7 to 66.5)61.2 (55.4 to 67.0)53.6 (47.7 to 59.6)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0439 (Threshold for significance at 0.0167 level.) · Stratified percentage difference: 7.1 · 98.3% CI -1.3 to 15.4
  • Zavegepant 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0302 (Threshold for significance at 0.0167 level.) · Stratified percentage difference: 7.5 · 98.3% CI -0.8 to 15.9
SecondaryPercentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose

Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose31.7 (25.8 to 37.5)34.5 (28.4 to 40.5)34.7 (28.8 to 40.6)27.4 (21.8 to 32.9)
SecondaryPercentage of Participants With Rescue Medication Use Within 24 Hours Post-dose

Participants who did not experience relief of their migraine headache at the end of 2 hours after dosing with study medication (and after the 2-hour assessments had been completed on the eCOA handheld device) were permitted to use the following rescue medications: aspirin, ibuprofen, acetaminophen up to 1000 mg/day (this includes Excedrin® Migraine), naproxen (or any other type of nonsteroidal anti-inflammatory drug), antiemetics (for example, metoclopramide or promethazine), or baclofen. The participant's use of rescue medication was recorded by the site on a case report form.

Time frame:
Through 24 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose24.9 (19.7 to 30.2)26.0 (20.7 to 31.4)20.2 (15.3 to 25.0)27.3 (21.9 to 32.6)
SecondaryPercentage of Participants With Freedom From Photophobia at 2 Hours Post-dose

Photophobia (sensitivity to light) status was measured as absent or present in the eCOA handheld device. Freedom from photophobia was defined as photophobia absent post-dose in the subset of participants with photophobia present at on-study migraine attack onset.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose35.0 (28.8 to 41.2)35.6 (29.4 to 41.8)37.9 (31.7 to 44.0)30.4 (24.6 to 36.3)
SecondaryPercentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose

Phonophobia (sensitivity to sound) status was measured as absent or present in the eCOA handheld device. Freedom from phonophobia was defined as phonophobia absent post-dose in the subset of participants with phonophobia present at on-study migraine attack onset.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose44.2 (36.9 to 51.6)44.8 (37.1 to 52.5)43.3 (36.0 to 50.7)34.1 (27.2 to 40.9)
SecondaryPercentage of Participants With Pain Relief at 60 Minutes Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

Time frame:
60 minutes post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Pain Relief at 60 Minutes Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Pain Relief at 60 Minutes Post-dose47.0 (41.0 to 53.1)46.0 (40.0 to 52.1)49.8 (43.8 to 55.7)41.9 (36.0 to 47.8)
SecondaryPercentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose

Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

Time frame:
60 minutes post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose22.6 (17.3 to 27.8)18.9 (13.9 to 23.9)18.8 (14.0 to 23.7)17.1 (12.4 to 21.8)
SecondaryPercentage of Participants With Pain Relief at 30 Minutes Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

Time frame:
30 minutes post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Pain Relief at 30 Minutes Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Pain Relief at 30 Minutes Post-dose26.6 (21.2 to 32.0)29.9 (24.4 to 35.5)26.6 (21.3 to 31.9)24.7 (19.5 to 29.8)
SecondaryPercentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose

Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

Time frame:
30 minutes post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose8.8 (5.3 to 12.4)7.6 (4.2 to 11.0)9.9 (6.2 to 13.7)5.4 (2.6 to 8.2)
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 24 hours post-dose.

Time frame:
From 2 hours up to 24 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose43.7 (37.6 to 49.7)42.5 (36.5 to 48.4)44.5 (38.6 to 50.5)35.7 (29.9 to 41.4)
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 24 hours post-dose.

Time frame:
From 2 hours up to 24 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose14.2 (10.0 to 18.5)15.1 (10.8 to 19.4)15.7 (11.3 to 20.0)9.0 (5.6 to 12.4)
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 48 hours post-dose.

Time frame:
From 2 hours up to 48 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose40.1 (34.1 to 46.0)39.6 (33.7 to 45.6)38.8 (33.0 to 44.6)32.7 (27.1 to 38.3)
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 48 hours post-dose.

Time frame:
From 2 hours up to 48 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose12.9 (8.8 to 17.0)13.8 (9.6 to 18.0)13.2 (9.1 to 17.2)7.5 (4.3 to 10.6)
SecondaryPercentage of Participants With Freedom From Nausea at 2 Hours Post-dose

Nausea status was measured as absent or present in the eCOA handheld device. Freedom from nausea was defined as nausea absent post-odse in the subset of participants with nausea present at on-study migraine attack onset.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose53.2 (45.4 to 60.9)53.9 (46.3 to 61.6)54.7 (47.4 to 62.0)51.0 (43.3 to 58.8)
SecondaryPercentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relapse was defined as pain level of mild, moderate, or severe after 2 hours up to 48 hours post-dose in the subset of participants with pain level of none at 2 hours post-dose.

Time frame:
From 2 hours up to 48 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose
percentage of participantsZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose31.6 (18.8 to 44.3)33.0 (21.0 to 45.0)37.6 (25.6 to 49.7)50.0 (34.8 to 65.2)

Adverse events

Collected over Adverse events were assessed from study drug dosing up to the end of the study (up to 52 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zavegepant 5 mg0/388 (0%)0/388 (0%)57/388 (14.7%)
Zavegepant 10 mg0/394 (0%)1/394 (0.3%)58/394 (14.7%)
Zavegepant 20 mg0/403 (0%)0/403 (0%)81/403 (20.1%)
Placebo0/403 (0%)1/403 (0.2%)15/403 (3.7%)
Most frequent serious events
Most frequent serious events
EventZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
ThrombosisVascular disorders0/3881/3940/4030/403
Vestibular migraineNervous system disorders0/3880/3940/4031/403
Most frequent other events
Most frequent other events
EventZavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlacebo
DysgeusiaNervous system disorders54/38853/39465/40314/403
Nasal discomfortRespiratory, thoracic and mediastinal disorders5/3885/39421/4031/403

Baseline characteristics

Treated Participants included enrolled participants who took study therapy (zavegepant or placebo).

Age, Continuous
Age, Continuous(years)Zavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlaceboTotal
Mean41.9 ± 12.5841.3 ± 12.9640.0 ± 12.9540.0 ± 12.0740.8 ± 12.66
Sex: Female, Male
Sex: Female, Male(Participants)Zavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlaceboTotal
Female3373353443381354
Male51595965234
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlaceboTotal
Hispanic or Latino64697281286
Not Hispanic or Latino3243253313221302
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlaceboTotal
American Indian or Alaska Native20316
Asian1713151358
Native Hawaiian or Other Pacific Islander01001
Black or African American65746259260
White2992973163291241
More than one race597122
Unknown or Not Reported00000
Prophylactic migraine medication use at randomization
Prophylactic migraine medication use at randomization(Participants)Zavegepant 5 mgZavegepant 10 mgZavegepant 20 mgPlaceboTotal
Yes54505755216
No3343443463481372
08

Study locations

82 sites
  • Coastal Clinical Research, Inc.
    Mobile, Alabama 36608, United States
  • Elite Clinical Studies
    Phoenix, Arizona 85018, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • eStudySite
    La Mesa, California 91942, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • National Research Institute
    Panorama City, California 91402, United States
  • Optimus Medical Group
    San Francisco, California 94102, United States
  • Neurological Research Institute
    Santa Monica, California 90404, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Denver Neurological Research, LLC
    Denver, Colorado 80210, United States
  • CT Clinical Research
    Cromwell, Connecticut 06416, United States
  • Ki Health Partners, LLC, dba New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Multi-Specialty Research Associates, Inc.
    Lake City, Florida 32055, United States
  • AGA Clinical Trials
    Miami, Florida 33012, United States
  • Qps Mra, Llc
    Miami, Florida 33143, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Ormond Medical Arts Pharmaceutical Research Center
    Ormond Beach, Florida 32174, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Premiere Research Institute
    West Palm Beach, Florida 33407, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Meridian Clinical Research
    Savannah, Georgia 31405, United States
  • Family Medicine Specialists/CIS
    Wauconda, Illinois 60084, United States
  • Phoenix Medical Research
    Prairie Village, Kansas 66208, United States
  • Crescent City Headache and Neurology Center, LLC
    Chalmette, Louisiana 70043, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana 70119, United States
  • DelRicht Research
    New Orleans, Louisiana 70124, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Community Clinical Research Network
    Marlborough, Massachusetts 01752, United States
  • Regeneris Medical
    North Attleboro, Massachusetts 02169, United States
  • MedVadis Research Corporation
    Watertown, Massachusetts 02472, United States
  • Michigan Head Pain & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinical Research Institute, Inc.
    Minneapolis, Minnesota 55402, United States
  • Clinical Research Institute, Inc.
    Plymouth, Minnesota 55441, United States
  • MedPharmics, LLC
    Biloxi, Mississippi 39531, United States
  • Center for Pharmaceutical Research, LLC
    Kansas City, Missouri 64114, United States
  • Meritas Health Neurology
    North Kansas City, Missouri 64116, United States
  • Sundance Clinical Research, LLC
    Saint Louis, Missouri 63141, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • QPS Bio-Kinetic Clinical Applications, LLC
    Springfield, Missouri 65802, United States
  • Clinvest Research LLC
    Springfield, Missouri 65810, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Dent Neurosciences Research Center
    Amherst, New York 14226, United States
  • Montefiore Medical Center: Headache Center
    Bronx, New York 10461, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Upstate Clinical Research Associates, LLC
    Williamsville, New York 14221, United States
  • PMG Research of Charlotte, LLC
    Charlotte, North Carolina 28209, United States
  • Headache Wellness Center
    Greensboro, North Carolina 27405, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • PMG Research of Raleigh, LLC
    Raleigh, North Carolina 27609, United States
  • Wilmington Health, PLLC
    Wilmington, North Carolina 28401, United States
  • Hometown Urgent Care and Research
    Cincinnati, Ohio 45215, United States
  • Hometown Urgent Care and Research
    Columbus, Ohio 43214, United States
  • Hometown Urgent Care and Research
    Dayton, Ohio 45424, United States
  • Hightower Clinical
    Oklahoma City, Oklahoma 73134, United States
  • Summit Research Network (Oregon) Inc.
    Portland, Oregon 97210, United States
  • Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
    Salem, Oregon 97301, United States
  • Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Meridian Clinical Research
    Dakota Dunes, South Dakota 57049, United States
  • Alliance for Multispecialty Research/New Orleans Center for Clinical Research/Volunteer Research
    Knoxville, Tennessee 37920, United States
  • Clinical Neuroscience Solutions DBA CNS Healthcare
    Memphis, Tennessee 38119, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75231, United States
  • Ventavia Research Group
    Fort Worth, Texas 76104, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • Red Star Research, LLC
    Lake Jackson, Texas 77566, United States
  • Advanced Pharmaceutical Development Clinical Research
    Magnolia, Texas 77355, United States
  • Victorium Clinical Research
    San Antonio, Texas 78230, United States
  • Dynamed Clinical Research
    Tomball, Texas 77375, United States
  • Wasatch Clinical Research, LLC
    Salt Lake City, Utah 84107, United States
  • Charlottesville Medical Research Center, LLC
    Charlottesville, Virginia 22911, United States
  • Tidewater Integrated Medical Research
    Virginia Beach, Virginia 23454, United States
  • Northwest Clinical Research
    Bellevue, Washington 98007, United States
  • Clinical Investigation Specialists, Inc.
    Kenosha, Wisconsin 53144, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Oct 2019, 7 months.

Results were first posted in Oct 2022, 2 years 11 months after primary completion. A results delay was requested in Sep 2020.

Of 12 phase 2/3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2019
First posted
Mar 13, 2019
StartActual
Mar 25, 2019
Primary completionActual
Oct 31, 2019
CompletionActual
Nov 11, 2019
Results delay requested
Sep 18, 2020
Results first posted
Oct 13, 2022
Last update
Sep 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03872453
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 13, 2019
Start date
Mar 25, 2019
Primary completion
Oct 31, 2019
Completion
Nov 11, 2019
Results posted
Oct 13, 2022
Last update
Sep 25, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zavegepant

Start the discussion